Vaxneuvance 32 µg Suspension for Injection
PDF Leaflet Revision Date: 13 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunization against invasive disease and pneumonia caused by Streptococcus pneumoniae.
Dosage (summary)
0.5 mL IM for adults; 3 doses for infants, with a booster at 11-15 months.
Special Populations
- Elderly (u2265 65 years)
- Preterm infants
- Individuals with HIV
Pregnancy & Breastfeeding
Use only if clearly needed during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Concomitant with inactivated influenza vaccine
- Immunosuppressive therapies may reduce immune response
Contraindications
- Severe allergic reaction to any component or diphtheria toxoid-containing vaccine
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Fever
Counselling Points
- Shake vigorously before use
- Do not inject if discolored or contains particulates
- Administer IM only
Serious warnings
- Altered immunocompetence may reduce immune response
- Risk of apnea in preterm infants
Important Disclaimer
The Vaxneuvance 32 µg Suspension for Injection professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
